CANCERS 润色咨询

Cancers

出版年份：暂无数据 年文章数：15725 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：2.0% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=921840, encodeId=8dbd921840c9, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0<br>偏重的研究方向：非编码RNA;肿瘤免疫<br>经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0ea5440576, createdName=弹珠1253, createdTime=Mon Feb 01 09:24:55 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：生信<br>经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向：肿瘤<br>经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤<br>经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问，接收meta吗，接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：生物信息学;肿瘤;生信<br>经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2021-02-01 弹珠1253

    审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0
    偏重的研究方向：非编码RNA;肿瘤免疫
    经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！

    7

    展开7条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=921840, encodeId=8dbd921840c9, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0<br>偏重的研究方向：非编码RNA;肿瘤免疫<br>经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0ea5440576, createdName=弹珠1253, createdTime=Mon Feb 01 09:24:55 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：生信<br>经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向：肿瘤<br>经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤<br>经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问，接收meta吗，接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：生物信息学;肿瘤;生信<br>经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2024-02-19 jobhnw 来自安徽省

    2024年中科院预警杂志

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=921840, encodeId=8dbd921840c9, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0<br>偏重的研究方向：非编码RNA;肿瘤免疫<br>经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0ea5440576, createdName=弹珠1253, createdTime=Mon Feb 01 09:24:55 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：生信<br>经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向：肿瘤<br>经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤<br>经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问，接收meta吗，接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：生物信息学;肿瘤;生信<br>经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2022-11-09 赵文超

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向：生信
    经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。

    7

    展开7条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=921840, encodeId=8dbd921840c9, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0<br>偏重的研究方向：非编码RNA;肿瘤免疫<br>经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0ea5440576, createdName=弹珠1253, createdTime=Mon Feb 01 09:24:55 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：生信<br>经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向：肿瘤<br>经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤<br>经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问，接收meta吗，接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：生物信息学;肿瘤;生信<br>经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2024-01-22 地球超人 来自广东省

    麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=921840, encodeId=8dbd921840c9, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0<br>偏重的研究方向：非编码RNA;肿瘤免疫<br>经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0ea5440576, createdName=弹珠1253, createdTime=Mon Feb 01 09:24:55 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：生信<br>经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向：肿瘤<br>经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤<br>经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问，接收meta吗，接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：生物信息学;肿瘤;生信<br>经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2024-01-01 ms7000000858427135 来自四川省

    偏重的研究方向：肿瘤
    经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=921840, encodeId=8dbd921840c9, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0<br>偏重的研究方向：非编码RNA;肿瘤免疫<br>经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0ea5440576, createdName=弹珠1253, createdTime=Mon Feb 01 09:24:55 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：生信<br>经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向：肿瘤<br>经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤<br>经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问，接收meta吗，接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：生物信息学;肿瘤;生信<br>经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2023-10-28 ms7000001936665666 来自湖北省

    请问Pending review状态要持续几天呀？

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=921840, encodeId=8dbd921840c9, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0<br>偏重的研究方向：非编码RNA;肿瘤免疫<br>经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0ea5440576, createdName=弹珠1253, createdTime=Mon Feb 01 09:24:55 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：生信<br>经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向：肿瘤<br>经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤<br>经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问，接收meta吗，接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：生物信息学;肿瘤;生信<br>经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2023-12-21 1226054bm42暂无昵称 来自广东省

    审稿速度:1.0 | 投稿命中率:95.0
    偏重的研究方向：肿瘤
    经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=921840, encodeId=8dbd921840c9, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0<br>偏重的研究方向：非编码RNA;肿瘤免疫<br>经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0ea5440576, createdName=弹珠1253, createdTime=Mon Feb 01 09:24:55 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：生信<br>经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向：肿瘤<br>经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤<br>经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问，接收meta吗，接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：生物信息学;肿瘤;生信<br>经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2023-07-14 ms2000001241808309 来自山东省

    求问，接收meta吗，接不接受癌症护理方面的meta

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=921840, encodeId=8dbd921840c9, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0<br>偏重的研究方向：非编码RNA;肿瘤免疫<br>经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0ea5440576, createdName=弹珠1253, createdTime=Mon Feb 01 09:24:55 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：生信<br>经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向：肿瘤<br>经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤<br>经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问，接收meta吗，接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：生物信息学;肿瘤;生信<br>经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2023-07-11 ms8000001285062090 来自江苏省

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：生物信息学;肿瘤;生信
    经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=921840, encodeId=8dbd921840c9, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2468.0<br>偏重的研究方向：非编码RNA;肿瘤免疫<br>经验分享：2020.12.9投稿，western blot数据需要提供原始图片。2020.12.15号送审，每个作者都需要用edu邮箱，没有的话好像要提供简历用来说明。2021.1.5一审大修返回，其中两个审稿人意见很多，问得非常细致。2021.1.15一审修改提交。2021.1.21二审小修返回，之前两个审稿人一个没问题了，另一个又提了4个问题，很严谨。2021.1.25二审修改提交。2021.2.1接收。整体感觉工作效率很高，对数据量有一定要求，再有点创新性的话还是值得一试的，希望大家都有好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0ea5440576, createdName=弹珠1253, createdTime=Mon Feb 01 09:24:55 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188107, encodeId=a2f5218810e05, content=2024年中科院预警杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Mon Feb 19 09:41:15 CST 2024, time=2024-02-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099452, encodeId=aa222099452e8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：生信<br>经验分享：生信干湿结合的文章，做的是肿瘤药物敏感性和标记物的方向，一开始也陆续投了十几个期刊，基本上都是被秒拒，最后投的这个杂志，10月13号投稿，两个礼拜审稿人意见回来了，给了十天时间返修，11月8号接收，效率真的很高，建议所有作者都要用edu邮箱，不然会被编辑要求提供CV。有很多朋友都说发文量大，明年可能被降到二区，但是对于急着毕业或者申请职称的医生还是很友好的，同样的期刊还有cancer science, genes，好像都是MDPI旗下的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLual6qbF39miaQ8KnlQp1YZEGKhrTttZD7oCRyicxuoGtibMN5F8z79hBcQ9n1hGicKvcRf0icVzyNEmQ/132, createdBy=b92a2216940, createdName=赵文超, createdTime=Wed Nov 09 19:12:49 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183248, encodeId=8a0e2183248d1, content=麻烦请教大家，这个杂志必须所有作者，都要去点击邮件里那个“同意发表”才行吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=地球超人, createdTime=Mon Jan 22 18:13:48 CST 2024, time=2024-01-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2178658, encodeId=265c21e8658c4, content=偏重的研究方向：肿瘤<br>经验分享：只有一个细胞系的，会被拒吗？……小鼠转移肺癌模型的，除了llc细胞，还能有啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d3e5341780, createdName=ms7000000858427135, createdTime=Mon Jan 01 23:09:49 CST 2024, time=2024-01-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165372, encodeId=ca2921653e244, content=请问Pending review状态要持续几天呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bf85627337, createdName=ms7000001936665666, createdTime=Sat Oct 28 09:04:52 CST 2023, time=2023-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176414, encodeId=6b7921e64144b, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤<br>经验分享：从投稿，送审，返修，到接收，整个过程非常快，不到一个月。编辑和期刊工作效率很高，也很nice。目前还是williamhill asia 医院推荐的投稿期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Thu Dec 21 22:46:31 CST 2023, time=2023-12-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2147934, encodeId=6b38214e9345c, content=求问，接收meta吗，接不接受癌症护理方面的meta, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71568621525, createdName=ms2000001241808309, createdTime=Fri Jul 14 00:43:05 CST 2023, time=2023-07-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147553, encodeId=e9b0214e553b4, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：生物信息学;肿瘤;生信<br>经验分享：投稿到接收不到一个月，大概2天送审，5天小修，wb需要整膜，总的来说，快，创新性要求蛮高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088b8137007, createdName=ms8000001285062090, createdTime=Tue Jul 11 22:19:22 CST 2023, time=2023-07-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2097492, encodeId=cc45209e492b8, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38265396482, createdName=ms9000000045361890, createdTime=Sun Oct 30 17:36:55 CST 2022, time=2022-10-30, status=1, ipAttribution=)]
    2022-10-30 ms9000000045361890

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤
    经验分享：很好的一个杂志，审稿人提的意见非常有建设性，一审一个月整，就是版面费贵，投稿时格式有些要求

    3

    展开3条回复
共301条页码: 1/31页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分